Lactitol, a second-generation disaccharide for treatment of chronic portal-systemic encephalopathy. A double-blind, crossover, randomized clinical trial

Digestive Diseases and Sciences
M UribeL Guevara

Abstract

A double-blind crossover trial was performed to test the therapeutic usefulness and safety of lactitol, a beta-galactoside sorbitol, against lactose in 18 patients with chronic portal-systemic encephalopathy (PSE). The study included four periods: two for washout and two for lactitol and lactose administration. During washout periods, which lasted two weeks each, patients were stabilized with neomycin plus milk of magnesia. Lactitol and lactose were administered during four weeks each. Ten patients were randomly assigned to receive lactose (group A) and eight patients to receive lactitol (group B) first. PSE parameters, ie, mental state, number connection test performance, asterixis and blood ammonia levels were assessed fortnightly. Electroencephalographic tracings and stool pHs were evaluated at the end of each study period. After the first administration of lactose and lactitol, no statistically significant differences in PSE parameters were found. At the same stage, a significant stool acidification (P less than 0.05) was detected. It is concluded that lactitol seems to be safe and efficacious in treating patients with chronic PSE.

References

Jul 1, 1979·Journal of Agricultural and Food Chemistry·J A van Velthuijsen
Jul 1, 1979·British Journal of Clinical Pharmacology·M Hills, P Armitage
Jul 1, 1974·The American Journal of Clinical Nutrition·R LiskerP Arroyo
Mar 1, 1955·Proceedings of the Society for Experimental Biology and Medicine·W V McDERMOTTA G RIDDELL

❮ Previous
Next ❯

Citations

May 1, 1993·Digestive Diseases and Sciences·C CammàL Pagliaro
Apr 16, 2016·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·Lise L GluudMarsha Y Morgan
Nov 1, 1990·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·M UribeC Coté
Feb 1, 1992·Hepatology : Official Journal of the American Association for the Study of Liver Diseases·P BlancH Michel
Sep 27, 2007·Alimentary Pharmacology & Therapeutics·E HuangB M R Spiegel
Jan 1, 1997·Scandinavian Journal of Gastroenterology. Supplement·M Uribe-EsquivelR M Muñoz

❮ Previous
Next ❯

Related Concepts

Related Feeds

Aminoglycosides

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.

Aminoglycosides (ASM)

Aminoglycoside is a medicinal and bacteriologic category of traditional Gram-negative antibacterial medications that inhibit protein synthesis and contain as a portion of the molecule an amino-modified glycoside. Discover the latest research on aminoglycoside here.